Close

Metacrine (MTCR) Commences Phase 2a Trial of MET642 for Treatment of Patients with NASH

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 4/19/2024

1. NFLX
2. TSM
3. ISRG
4. INFY
5. SNV
6. TSLA
7. SPY
8. SMCI
9. BX
10. AAPL


Go back to Metacrine (MTCR) Commences Phase 2a Trial of MET642 for Treatment of Patients with NASH
(NASDAQ: MTCR) Delayed: 0.49 --0 (-0%)
Previous Close $0.49    52 Week High $ 
Open $0.49    52 Week Low $ 
Day High $0.49    P/E N/A 
Day Low $0.49    EPS $ 
Volume 4,972,059